Table 2. Immunological responses in patients who received WT1 vaccine.
| WT1 tetramer, %
|
|||
|---|---|---|---|
| Patient no. | Before | After* | Immunological responses |
| Breast cancer | |||
| 1 | 0.78 | 0.34 | - |
| 2 | 0.12 | 0.25 | + |
| Lung cancer | |||
| 3 | 0.25 | 0.76 | + |
| 4 | 0.28 | 0.52 | + |
| 5 | 0.86 | ND | UE |
| 6 | 0.17 | 0.33 | + |
| 7 | 1.31 | ND | UE |
| 8 | 0.13 | 0.17 | - |
| 9 | 0.19 | 0.25 | - |
| 10 | 0.47 | 0.65 | - |
| 11 | 0.20 | 0.29 | - |
| 12 | 0.08 | 0.11 | - |
| Leukemia | |||
| 13 | 0.98 | ND | UE |
| 14 | 0.62 | 6.61 | + |
| 15 | 0.98 | 2.32 | + |
| 16 | 0.36 | 0.72 | + |
| 17 | 0.41 | 0.39 | - |
| 18 | 0.24 | 0.50 | + |
| 19 | 0.09 | 0.62 | + |
| 20 | 0.16 | 0.26 | + |
| 21 | 0.19 | 1.85 | + |
| 22 | 0.30 | 0.31 | - |
| 23 | 0.19 | 0.29 | + |
| 24 | 0.22 | 0.38 | + |
| 25 | 0.37 | 0.29 | - |
| 26 | 0.11 | 0.14 | - |
Bold numbers indicate the WT1-specific CTL frequencies that significantly (≥ 1.5-fold) increased after WT1 vaccination. ND, not determined. UE, unevaluable due to lack of the measurement of WT1-specific CTL frequencies after WT1 vaccination.
*
The highest ones among WT1-specific CTL frequencies determined after WT1 vaccination are shown.